表紙
市場調查報告書

中樞神經系統(CNS)生物標記的全球市場

Central Nervous System Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 567964
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
中樞神經系統(CNS)生物標記的全球市場 Central Nervous System Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供中樞神經系統(CNS)生物標記的全球市場調查,各市場概要,種類、用途、終端用戶、地區的市場趨勢,市場的促進、阻礙因素及課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 簡介

  • 市場定義
  • 調查手法

第2章 摘要整理

第3章 主要推論

第4章 市場概要

  • 市場概況
  • 波特的五力分析

第5章 市場動態

  • 推動因素
  • 阻礙因素
  • 市場機會
  • 市場課題

第6章 中樞神經系統(CNS)生物標記的種類

  • 安全性生物標記
  • 藥效生物標記
    • 藥效學標記
    • 效果預測生物標記
    • 預後生物標記
  • 檢驗生物標記

第7章 中樞神經系統(CNS)生物標記的全球市場:各市場區隔

  • 各用途
    • 藥物研發、開發
    • 個人化醫療
    • 疾病風險評估
    • 其他
  • 各終端用戶
    • 診斷實驗室
    • 門診病人診療後
    • 醫院
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南非

第8章 競爭情形

  • 合併、收購
  • 聯盟、合作、協定

第9章 企業簡介

  • Abastar Mdx, Inc.
  • Thermo Fisher Scientific
  • Abiant, Inc.
  • Merck & Co., Inc.
  • Diagenic Asa
  • Banyan Biomarkers
  • Avid Radiopharmaceuticals Inc.
  • Avacta Group Plc
  • 其他

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 47145

The global central nervous system biomarkers market is expected to register a CAGR of 12.5% over the forecast period. A biomarker is used to measure the biological state, presence of diseases and effects of treatments. With the advent of proteomics and genomics, the demand for central nervous system (CNS) biomarkers has increased. Due to rapid advancements in genomic technologies, genetics analyses have become essential in clinical practices and research. Moreover, with the advancement in technology, the CNS biomarker testing has become widely accessible and feasible, to perform even in small size laboratories. Certain CNS diseases are hereditary, which encouraged the search for common variant genes associated with nerve function and CNS disease phenotypes using genomic technologies. Furthermore, advanced imaging systems are aiding early diagnosis of various diseases, while reducing the mortality rate. Hence, the market studied is expected to witness steady growth over the forecast period, due to the development in proteomics, genomics, and imaging system.

Key Market Trends

Personalized Medicine Segment is Expected to Show Better Growth in the Forecast Years

Based on application, it is segmented into drug discovery & development, personalized medicine, and others. Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackle diseases. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing breakthrough products for the treatment of neurological disease. In addition, to support the advancement of precision medicine in chronic diseases, the former President of the United States, Barrack Obama announced the Precision Medicine Initiative (PMI) in 2015. The PMI was awarded USD 215 million investment in 2016, primarily aimed at accelerating biomedical research while providing clinicians with new tools and therapies for selecting biomarkers that will work best for individual patients. Hence, with the various government initiatives and wide applications of biomarkers in personalized medicine, the market is expected to grow better over the forecast period.

North America Dominates the Central Nervous System Biomarkers Market

The Central Nervous System Biomarkers market holds the largest share in the North America region. According to the American Cancer Society, approximately 1,735,350 new cancer cases were diagnosed in the United States in 2018 and there were around 609,640 deaths during the same year. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the central nervous system biomarkers market are - Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd., Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories, Inc., DiaGenic ASA, G-Biosciences, Merck KGaA and Thermo Fisher Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Development in Proteomics, Genomics and Imaging System
    • 4.2.2 Rising Investments from Government and Private Players
    • 4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers
  • 4.3 Market Restraints
    • 4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics
    • 4.3.2 Reimbursement and Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of CNS Biomarkers
    • 5.1.1 Safety Biomarker
    • 5.1.2 Efficacy Biomarker
    • 5.1.3 Validation Biomarker
    • 5.1.4 Other
  • 5.2 By Application
    • 5.2.1 Drug Discovery & Development
    • 5.2.2 Personalized Medicine
    • 5.2.3 Others
  • 5.3 By End User
    • 5.3.1 Diagnostic Labs
    • 5.3.2 Clinics/Hospitals
    • 5.3.3 Research Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Acumen Pharmaceuticals Inc.
    • 6.1.2 Alseres Pharmaceuticals Inc.
    • 6.1.3 Aposense Ltd.
    • 6.1.4 Avacta Life Sciences Limited
    • 6.1.5 Banyan Biomarkers Inc.
    • 6.1.6 Bio-Rad Laboratories, Inc.
    • 6.1.7 DiaGenic ASA
    • 6.1.8 G-Biosciences
    • 6.1.9 Merck KGaA
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS